Based on its in vitro activity profile, we hypothesized that in vivo therapy with LMP-420 would decrease intestinal production of pro-inflammatory cytokines including TNF and thus decrease intestinal inflammation in IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.